NCT04282018 2026-02-20Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and TislelizumabBeOne MedicinesPhase 1/2 Completed97 enrolled 43 charts
NCT06697184 2025-12-17A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.BeOne MedicinesPhase 1/2 Active not recruiting56 enrolled
NCT07052695 2025-12-15Mosunetuzumab for CLL MRD ClearanceDana-Farber Cancer InstitutePhase 1/2 Recruiting40 enrolled
NCT04172246 2025-11-21Study of Zanubrutinib in Japanese Participants With B-Cell MalignanciesBeOne MedicinesPhase 1/2 Completed55 enrolled